サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1660891

スタチンの世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）

Statins Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 189 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
スタチンの世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年02月14日
発行: Persistence Market Research
ページ情報: 英文 189 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のスタチンの市場規模は、2025年に166億米ドルになるとみられ、2025年～2032年の予測期間に3.1%のCAGRで拡大し、2032年には206億米ドルに達すると予測されています。

スタチン市場は、主に心血管疾患や高脂血症の患者に処方され、コレステロール値を低下させるために広く使用されている薬剤を網羅しています。スタチンは予防ヘルスケアに不可欠な要素であり、心臓発作、脳卒中、その他の心血管合併症のリスク軽減に役立ちます。同市場にはスタチンを主成分とする様々な薬剤があり、複数の大手企業が世界市場を牽引しています。スタチン市場の成長は、心血管疾患の世界の有病率の増加、心臓の健康に対する意識の高まり、患者のコンプライアンス向上を目的としたスタチン製剤の進歩によってもたらされます。

スタチン市場は主に、特に高齢化社会における心血管疾患の世界の負担増によって牽引されています。スタチンはコレステロール値の管理に重要な役割を果たすため、心臓に関連する重篤な疾患の予防につながります。さらに、予防ヘルスケア対策に対する認識と受容の高まりが、高齢者人口の拡大と相まって、スタチン系薬剤の需要に拍車をかけています。薬剤製剤の進歩や、副作用の少ない新世代スタチンは、市場の成長をさらに促進しています。さらに、ヘルスケアを推進する政府の取り組みや、スタチン処方をカバーする健康保険の普及が、市場の前向きな見通しに寄与しています。

スタチン市場には大きな機会があり、特にスタチンと他のコレステロール低下薬や心臓病治療薬との併用療法への注目が高まっています。安全性と有効性が改善された新型スタチンの開発は、市場のアンメットニーズに応える可能性があります。さらに、特に新興市場において、心臓病の予防に対する世界の関心が高まっていることも、有利な機会をもたらしています。患者教育、手頃な価格設定モデル、革新的な流通チャネルによる市場アクセスの拡大に投資する企業は、大きな成長を遂げる可能性が高いです。さらに、個別化医療や精密医療に対する需要の高まりは、オーダーメイドのスタチン療法の可能性をもたらしています。

当レポートでは、世界のスタチン市場について調査し、薬剤クラス別、治療別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲と定義
  • 市場力学
  • マクロ経済要因
  • COVID-19の影響分析
  • 予測要因- 関連性と影響

第3章 付加価値の洞察

第4章 世界のスタチン市場の見通し

  • 主なハイライト
  • 市場規模（10億米ドル）分析と予測
  • 世界のスタチン市場の見通し：薬剤クラス別
  • 世界のスタチン市場の見通し：治療別
  • 世界のスタチン市場の見通し：エンドユーザー別

第5章 世界のスタチン市場の見通し：地域別

  • 主なハイライト
  • 過去の市場規模（10億米ドル）分析、地域別、2019年～2024年
  • 現在の市場規模（10億米ドル）の分析と予測、地域別、2025年～2032年
  • 市場の魅力分析：地域別

第6章 北米のスタチン市場の見通し

第7章 欧州のスタチン市場の見通し

第8章 東アジアのスタチン市場の見通し

第9章 南アジアおよびオセアニアのスタチン市場の見通し

第10章 ラテンアメリカのスタチン市場の見通し

第11章 中東・アフリカのスタチン市場の見通し

第12章 競合情勢

  • 市場シェア分析、2025年
  • 市場構造
  • 企業プロファイル（詳細- 概要、財務、戦略、最近の動向）
    • Pfizer Inc.
    • Centrient Pharmaceuticals Netherlands B.V.
    • CMP Pharma, Inc.
    • AstraZeneca
    • Salerno Pharma
    • Kowa Pharmaceuticals America, Inc.
    • Medicure Pharma
    • Covis Pharma
    • Novartis AG
    • Teva Pharmaceuticals USA, Inc.
    • Lupin
    • AdvaCare Pharma(R)
    • Arlak Corazon
    • Merck & Co., Inc.
    • CTX Lifesciences
    • Biofield Pharma
    • Organon group of companies
    • Taj Pharmaceuticals Limited
    • Aurobindo Pharma USA
    • Biocon

第13章 付録

目次
Product Code: PMRREP3038

Persistence Market Research has recently published an extensive report on the global Statins Market. This report offers a comprehensive analysis of the key market dynamics, including drivers, trends, opportunities, and challenges, providing deep insights into the market structure.

Key Insights:

  • Statins Market Size (2025E): USD 16.6 Bn
  • Projected Market Value (2032F): USD 20.6 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032): 3.1%

Statins Market - Report Scope:

The Statins Market encompasses medications widely used to lower cholesterol levels, primarily prescribed to patients with cardiovascular diseases and hyperlipidemia. Statins are an essential component of preventive healthcare, helping to reduce the risk of heart attacks, strokes, and other cardiovascular complications. The market includes a variety of statin-based drugs, with several major players leading the global market. Growth in the Statins Market is driven by an increasing global prevalence of cardiovascular diseases, growing awareness about heart health, and advancements in statin formulations aimed at improving patient compliance.

Market Growth Drivers:

The Statins Market is primarily driven by the rising global burden of cardiovascular diseases, especially in aging populations. Statins play a key role in managing cholesterol levels, thereby preventing serious heart-related conditions. Additionally, increasing awareness and acceptance of preventive healthcare measures, combined with the expanding geriatric population, are fueling demand for statin drugs. Advancements in drug formulations and new generational statins offering fewer side effects further enhance market growth. Furthermore, government initiatives promoting healthcare and the rising adoption of health insurance policies that cover statin prescriptions are contributing to the market's positive outlook.

Market Restraints:

Despite positive growth, the Statins Market faces several challenges. These include the increasing concerns over the long-term side effects of statins, such as muscle pain and liver damage, which may discourage some patients from using these drugs. The market also faces growing competition from generic statins, which have reduced the revenue potential for branded products. Additionally, the increasing trend toward personalized medicine, along with alternative cholesterol-lowering treatments, presents competition to statins. Regulatory hurdles and pricing pressures in developing regions may also restrict market growth, especially where access to statin drugs is limited.

Market Opportunities:

There are significant opportunities in the Statins Market, particularly with the growing focus on combination therapies that pair statins with other cholesterol-lowering or heart-health medications. The development of newer statins with improved safety profiles and efficacy could cater to unmet needs in the market. Moreover, the increasing global focus on the prevention of heart disease, particularly in emerging markets, presents lucrative opportunities. Companies that invest in patient education, affordable pricing models, and expanding market access through innovative distribution channels are likely to see substantial growth. Additionally, the rising demand for personalized and precision medicine offers potential for tailored statin therapies.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the Statins Market globally?
  • Which statin formulations are leading the market, and how are they being adopted in various therapeutic areas?
  • How are technological advancements influencing the competitive landscape of the Statins Market?
  • Who are the key players in the Statins Market, and what strategies are they employing to stay competitive?
  • What are the emerging trends and future prospects in the global Statins Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Statins Market, including Pfizer Inc., Merck & Co., and AstraZeneca, are focusing on product innovation, extensive research and development efforts, and strategic partnerships to maintain a competitive edge. These companies are increasingly investing in expanding their portfolios to include combination therapies and statins with fewer side effects. Collaboration with healthcare providers, hospitals, and pharmaceutical distributors is key to market access and ensuring greater reach of statin products. In addition, maintaining a focus on patient education, adherence programs, and global market penetration through emerging economies are important business strategies for success in the Statins Market.

Key Companies Profiled:

  • Pfizer Inc.
  • Centrient Pharmaceuticals Netherlands B.V.
  • CMP Pharma, Inc.
  • AstraZeneca
  • Salerno Pharma
  • Kowa Pharmaceuticals America, Inc.
  • Medicure Pharma
  • Covis Pharma
  • Novartis AG
  • Teva Pharmaceuticals USA, Inc.
  • Lupin
  • AdvaCare Pharma(R)
  • Arlak Corazon
  • Merck & Co., Inc.
  • CTX Lifesciences
  • Biofield Pharma
  • Organon group of companies
  • Taj Pharmaceuticals Limited
  • Aurobindo Pharma USA
  • Biocon

Statins Market Segmentation

By Drug Class

  • Atorvastatins
  • Fluvastatins
  • Lovastatins
  • Pravastatins
  • Simvastatins

By Therapeutic Treatment

  • Obesity
  • Cardiovascular Disorders
  • Inflammatory Disorders

By End User

  • Hospitals
  • Clinics

By Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Statins Market Snapshot, 2025 - 2032
  • 1.2. Market Opportunity Assessment, 2025 - 2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Drug Class Adoption Analysis
  • 3.2. Regulatory Landscape
  • 3.3. Value Chain Analysis
  • 3.4. PESTLE Analysis
  • 3.5. Porter's Five Force Analysis

4. Global Statins Market Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019 - 2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025 - 2032
  • 4.3. Global Statins Market Outlook: Drug Class
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019 - 2024
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
      • 4.3.3.1. Atorvastatins
      • 4.3.3.2. Fluvastatins
      • 4.3.3.3. Lovastatins
      • 4.3.3.4. Pravastatins
      • 4.3.3.5. Simvastatins
      • 4.3.3.6. Others
    • 4.3.4. Market Attractiveness Analysis: Drug Class
  • 4.4. Global Statins Market Outlook: Therapeutic Treatment
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn), By Therapeutic Treatment, 2019 - 2024
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Treatment, 2025 - 2032
      • 4.4.3.1. Obesity
      • 4.4.3.2. Cardiovascular Disorders
      • 4.4.3.3. Inflammatory Disorders
      • 4.4.3.4. Others
    • 4.4.4. Market Attractiveness Analysis: Therapeutic Treatment
  • 4.5. Global Statins Market Outlook: End User
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019 - 2024
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
      • 4.5.3.1. Hospitals
      • 4.5.3.2. Clinics
      • 4.5.3.3. Others
    • 4.5.4. Market Attractiveness Analysis: End User

5. Global Statins Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2024
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025 - 2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Statins Market Outlook

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 6.2.1. By Country
    • 6.2.2. By Drug Class
    • 6.2.3. By Therapeutic Treatment
    • 6.2.4. By End User
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    • 6.4.1. Atorvastatins
    • 6.4.2. Fluvastatins
    • 6.4.3. Lovastatins
    • 6.4.4. Pravastatins
    • 6.4.5. Simvastatins
    • 6.4.6. Others
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Treatment, 2025 - 2032
    • 6.5.1. Obesity
    • 6.5.2. Cardiovascular Disorders
    • 6.5.3. Inflammatory Disorders
    • 6.5.4. Others
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
    • 6.6.1. Hospitals
    • 6.6.2. Clinics
    • 6.6.3. Others
  • 6.7. Market Attractiveness Analysis

7. Europe Statins Market Outlook

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 7.2.1. By Country
    • 7.2.2. By Drug Class
    • 7.2.3. By Therapeutic Treatment
    • 7.2.4. By End User
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    • 7.4.1. Atorvastatins
    • 7.4.2. Fluvastatins
    • 7.4.3. Lovastatins
    • 7.4.4. Pravastatins
    • 7.4.5. Simvastatins
    • 7.4.6. Others
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Treatment, 2025 - 2032
    • 7.5.1. Obesity
    • 7.5.2. Cardiovascular Disorders
    • 7.5.3. Inflammatory Disorders
    • 7.5.4. Others
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
    • 7.6.1. Hospitals
    • 7.6.2. Clinics
    • 7.6.3. Others
  • 7.7. Market Attractiveness Analysis

8. East Asia Statins Market Outlook

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 8.2.1. By Country
    • 8.2.2. By Drug Class
    • 8.2.3. By Therapeutic Treatment
    • 8.2.4. By End User
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    • 8.4.1. Atorvastatins
    • 8.4.2. Fluvastatins
    • 8.4.3. Lovastatins
    • 8.4.4. Pravastatins
    • 8.4.5. Simvastatins
    • 8.4.6. Others
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Treatment, 2025 - 2032
    • 8.5.1. Obesity
    • 8.5.2. Cardiovascular Disorders
    • 8.5.3. Inflammatory Disorders
    • 8.5.4. Others
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
    • 8.6.1. Hospitals
    • 8.6.2. Clinics
    • 8.6.3. Others
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Statins Market Outlook

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 9.2.1. By Country
    • 9.2.2. By Drug Class
    • 9.2.3. By Therapeutic Treatment
    • 9.2.4. By End User
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    • 9.4.1. Atorvastatins
    • 9.4.2. Fluvastatins
    • 9.4.3. Lovastatins
    • 9.4.4. Pravastatins
    • 9.4.5. Simvastatins
    • 9.4.6. Others
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Treatment, 2025 - 2032
    • 9.5.1. Obesity
    • 9.5.2. Cardiovascular Disorders
    • 9.5.3. Inflammatory Disorders
    • 9.5.4. Others
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
    • 9.6.1. Hospitals
    • 9.6.2. Clinics
    • 9.6.3. Others
  • 9.7. Market Attractiveness Analysis

10. Latin America Statins Market Outlook

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 10.2.1. By Country
    • 10.2.2. By Drug Class
    • 10.2.3. By Therapeutic Treatment
    • 10.2.4. By End User
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    • 10.4.1. Atorvastatins
    • 10.4.2. Fluvastatins
    • 10.4.3. Lovastatins
    • 10.4.4. Pravastatins
    • 10.4.5. Simvastatins
    • 10.4.6. Others
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Treatment, 2025 - 2032
    • 10.5.1. Obesity
    • 10.5.2. Cardiovascular Disorders
    • 10.5.3. Inflammatory Disorders
    • 10.5.4. Others
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
    • 10.6.1. Hospitals
    • 10.6.2. Clinics
    • 10.6.3. Others
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Statins Market Outlook

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 11.2.1. By Country
    • 11.2.2. By Drug Class
    • 11.2.3. By Therapeutic Treatment
    • 11.2.4. By End User
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    • 11.4.1. Atorvastatins
    • 11.4.2. Fluvastatins
    • 11.4.3. Lovastatins
    • 11.4.4. Pravastatins
    • 11.4.5. Simvastatins
    • 11.4.6. Others
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Treatment, 2025 - 2032
    • 11.5.1. Obesity
    • 11.5.2. Cardiovascular Disorders
    • 11.5.3. Inflammatory Disorders
    • 11.5.4. Others
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
    • 11.6.1. Hospitals
    • 11.6.2. Clinics
    • 11.6.3. Others
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Pfizer Inc.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Drug Class
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Centrient Pharmaceuticals Netherlands B.V.
    • 12.3.3. CMP Pharma, Inc.
    • 12.3.4. AstraZeneca
    • 12.3.5. Salerno Pharma
    • 12.3.6. Kowa Pharmaceuticals America, Inc.
    • 12.3.7. Medicure Pharma
    • 12.3.8. Covis Pharma
    • 12.3.9. Novartis AG
    • 12.3.10. Teva Pharmaceuticals USA, Inc.
    • 12.3.11. Lupin
    • 12.3.12. AdvaCare Pharma(R)
    • 12.3.13. Arlak Corazon
    • 12.3.14. Merck & Co., Inc.
    • 12.3.15. CTX Lifesciences
    • 12.3.16. Biofield Pharma
    • 12.3.17. Organon group of companies
    • 12.3.18. Taj Pharmaceuticals Limited
    • 12.3.19. Aurobindo Pharma USA
    • 12.3.20. Biocon

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations